ImmunityBio Announces Combination with NantKwest to Create a Clinical-Stage Immunotherapy Leader

December 21, 2020
Transaction Overview
Our Opportunity to Lead in Immunotherapy

**Expansive clinical-stage pipeline and intellectual property.** 13 assets in clinical trials, including 11 in Phase II to III clinical trials, as well as a strong global intellectual property portfolio of over 400 issued and pending worldwide patent applications with patent life extending to 2035 and beyond.

**Differentiated technology and assets.** Best-in-class combined discovery and development platforms for novel therapies and next-generation early-stage candidates across immunotherapy, neoepitopes and molecules enhancing allogenic and autologous NK and T-cell therapies.

**Cutting-edge cell manufacturing expertise and ready-to-scale facilities.** Extensive and seasoned R&D, clinical trial, and regulatory operations and development teams, which together will occupy over 200,000 square feet of facilities devoted to manufacturing and R&D.

**Improved ability to combine platforms and therapies.** The transaction improves the ability to more seamlessly combine programs and leverage resources and expertise across both companies’ platforms, ultimately strengthening the efforts of both companies on behalf of patients to drive better outcomes in the fight against oncology and infectious disease.

**Significant potential for strategic and financial synergies.** This opportunity will come from meaningful streamlining of clinical operations, therapeutic discovery and development, and manufacturing.

---

**Transaction Overview**

- **Consolidated Pipeline**
- **ImmunityBio**
- **ImmunityBio – NantKwest Combinations**
- **Closing**
Combined Immunotherapy Platforms Better Positioned to Treat Patients

- **ImmunityBio**
  - Broad range of late-stage breakthrough designated immunotherapy platforms spanning NK and T cell platforms
  - Promising early stage clinical and pre-clinical pipeline spanning infectious disease and oncology

- **NantKwest**
  - Proprietary natural killer (NK) cell platform spanning off-the-shelf & autologous stem cell NK platform
  - Proprietary manufacturing processes and ready-to-scale facilities

- **MergeCo**
  - An immunotherapy leader focused on treating cancer and infectious diseases by orchestrating the innate (NK) and adaptive (T cell) immune system

Both companies strongly aligned in culture, operations, combination trials and collaboration agreements.

Transaction Overview | Consolidated Pipeline | ImmunityBio | ImmunityBio – NantKwest Combinations | Closing
---|---|---|---|---
Combined Pipeline Addresses Vast Unmet Needs Across Oncology and Infectious Disease

**Current ImmunityBio Programs**
- BCG Unresponsive NMIBC CIS
- BCG Unresponsive NMIBC Papillary
- 1L Squamous & Non-Squamous NSCLC – CPI Alone
- 1L Squamous & Non-Squamous NSCLC – CPI + Concurrent Chemo
- 2L or Greater Checkpoint Relapsed NSCLC
- Recurrent Glioblastoma
- HIV

**Current Combined Trial with NantKwest**
- 3L Metastatic Pancreatic Cancer
- 1L/2L Metastatic Pancreatic Cancer
- 3L or Greater TNBC
- Recurrent Merkel Cell Carcinoma

**Current Collaboration with NantKwest**
- COVID-19 Therapeutic
- COVID-19 Vaccine: Adeno S-Fusion + N-ETSD

Note: 1L, 2L, 3L represent 1st Line, 2nd Line and 3rd Line; BCG: Bacillus Calmette-Guerin; NMIBC: Non-muscle invasive bladder cancer; CIS: Carcinoma in-situ disease; CPI: Checkpoint inhibitor; NSCLC: Non-small cell lung cancer; TNBC: Triple negative breast cancer
Phase II / III Data in BCG-Unresponsive NMIBC CIS
Ongoing Study

ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate

- QUILT 3.032 study completes planned enrollment of BCG unresponsive non-muscle invasive bladder cancer CIS cohort with 59% probability of patients maintaining complete response for at least 12 months
- Over 85% of patients in this study have avoided a cystectomy to date
- Breakthrough status for ImmunityBio’s superagonist Anktiva N-803 in this indication
- Biological licensing application filing anticipated in second half of 2021

CULVER CITY, Calif., December 21, 2020 — ImmunityBio, Inc., a privately-held immunotherapy company, today announced positive data from the first cohort of a pivotal Phase 2/3 trial (QUILT 3.032) for non-muscle invasive bladder cancer in high risk carcinoma in situ (CIS) disease. The data showed 51 out of 71 evaluable patients (72%) had a complete response (at any time) to intravesical BCG plus N-803 (Anktiva), with 59% probability of these patients maintaining a complete response for at least 12 months, with a median duration of complete response of 19.2 months to date.

With the observed efficacy and only 1% of patients reporting treatment emergent serious adverse events, but none of which were treatment-related, the data support the potential for Anktiva + BCG as a novel option for BCG unresponsive CIS, a therapeutically challenging disease. Patients with BCG unresponsive CIS disease face surgical removal of the bladder, a procedure fraught with high morbidity and mortality.
## Significant Market Opportunity for Lead Programs

<table>
<thead>
<tr>
<th>Disease Area</th>
<th>Market Size</th>
<th>Targeted Patient Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG Unresponsive Non-Muscle Invasive Bladder Cancer</td>
<td>~81k</td>
<td>~18k Targeted patients in the U.S.</td>
</tr>
<tr>
<td>Non-Small Cell Lung Cancer</td>
<td>~106k</td>
<td>~21k patients in the U.S.</td>
</tr>
<tr>
<td>Pancreatic Cancer</td>
<td>~31k</td>
<td>~49k Targeted 1L and 2L, respectively, patients in the U.S.</td>
</tr>
<tr>
<td>COVID-19 Vaccine</td>
<td>~350mm</td>
<td>Targeted patients in the U.S.</td>
</tr>
</tbody>
</table>

### Cancer
- **BCG Unresponsive Non-Muscle Invasive Bladder Cancer**
  - ~81k Bladder cancer patients in the U.S.
  - ~18k Targeted patients in the U.S.

- **Non-Small Cell Lung Cancer**
  - 1L Squamous & Non-Squamous NSCLC
    - ~106k Targeted 1L patients in the U.S.
  - 2L or Greater Checkpoint Relapsed NSCLC
    - ~21k patients in the U.S.

- **Pancreatic Cancer**
  - 3L Metastatic Pancreatic Cancer
    - ~31k Targeted 3L patients in the U.S.
  - 1L/2L Metastatic Pancreatic Cancer
    - ~49k | ~39k Targeted 1L and 2L, respectively, patients in the U.S.

- **COVID-19 Vaccine**
  - ~350mm Targeted patients in the U.S.
Highly Experienced Management Team with Proven Track Record

Patrick Soon-Shiong, MD
Executive Chairman

Rich Adcock, MBA
CEO

David Sachs, MBA
CFO

Lennie Sender, MD
COO

Bobby Reddy, MD
CMO

Fabio Benedetti, MD
Chief Strategy Officer *

Steve Yang, JD
General Counsel

Sarah Singleton
Chief Marketing Officer

Shahrooz Rabizadeh, PhD
CSO

Kayvan Niazi, PhD
CTO

Maureen Becker
SVP, Human Resources

Hans Klingemann, MD, PhD
VP Research & Development

* Starting 04-Jan-2021

Transaction Overview  Consolidated Pipeline  ImmunityBio  ImmunityBio – NantKwest Combinations  Closing
## Transaction Details

### Key Transaction Terms
- New issuance ratio of **0.819** shares of NantKwest for every share of ImmunityBio
- Results in pro forma ownership of **72%** ImmunityBio shareholders and **28%** NantKwest shareholders

### Consideration Mix
- 100% stock-for-stock merger

### Timing / Approvals
- Subject to customary conditions, including NantKwest shareholder approval (including “majority of minority” shareholder approval)
- Expected to close in 1H 2020
Consolidated Pipeline
# Unparalleled Pipeline Across Oncology and Infectious Disease

<table>
<thead>
<tr>
<th>Phase</th>
<th>Target Indication</th>
<th>Pre-clinical</th>
<th>Ph I</th>
<th>Ph II</th>
<th>Ph III</th>
<th>ImmunityBio</th>
<th>NantKwest</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bladder</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II / III</td>
<td>BCG Unresponsive NMIBC Carcinoma In-Situ (CIS) Disease</td>
<td>Breakthrough &amp; Fast Track</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>II</td>
<td>BCG Unresponsive NMIBC Papillary Disease</td>
<td>Fast Track</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Lung</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>1L Squamous &amp; Non-Squamous NSCLC CPI Alone</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>III</td>
<td>1L NSCLC CPI + Concurrent Chemo</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>IIb</td>
<td>2L or Greater Checkpoint Relapsed NSCLC</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Glioblastoma</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>Recurrent Glioblastoma</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Pancreatic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II / III</td>
<td>3L Metastatic Pancreatic Cancer</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>II / III</td>
<td>1L / 2L Metastatic Pancreatic Cancer</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Breast</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ib/II</td>
<td>3L or Greater Triple Negative Breast Cancer</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Merkel</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>Recurrent Merkel Cell Carcinoma</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>COVID-19</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>COVID-19 Therapeutic</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>I / II / III</td>
<td>COVID-19 Vaccine Trials: TCELLVACCINE hAd5 S-Fusion + N-ETSD (SC, Oral)</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>HIV</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>Human Immunodeficiency Virus (HIV)</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Antibody Cytokine Fusion Proteins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-IND</td>
<td>Liquid Tumors: IL-15 Superagonist + Anti CD20 Fusion Protein</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Pre-IND</td>
<td>Solid Tumors: IL-15 Superagonist + Anti PD-L1 Fusion Protein</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Pre-IND</td>
<td>Solid Tumors: Tumor Necrosis Targeting (TNT)</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Pre-IND</td>
<td>Solid Tumors: Tumor Necrosis Targeting (TNT)</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>IND Auth</td>
<td>Diffuse Large B Cell Lymphoma</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Pre-IND</td>
<td>HER2+ Breast Cancer / Gastric Cancer</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Pre-IND</td>
<td>EGFR+ Squamous Cell Carcinoma</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Pre-IND</td>
<td>All Solid &amp; Liquid Tumors</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

**Clinical Stage**

**Late Stage Clinical Development: Aktiva**

**Infectious Disease**

**COVID-19**

**HIV**

**Antibody Cytokine Fusion Proteins**

**Pre-IND**

**NK Platform**

**CD19 t-haNK**

**HER2 t-haNK**

**EGFR t-haNK**

**M-ceNK**

**Transaction Overview**

**Consolidated Pipeline**

**ImmunityBio**

**ImmunityBio – NantKwest Combinations**

**Closing**
Unparalleled Immunotherapy Platform

**Core Modalities**

**Antibody Cytokine Fusion Proteins**
- Activating NK & T Cells

**Synthetic Immunomodulators**
- Tumoricidal Macrophages

**Vaccine Technologies**
- Memory T Cells

**NantKwest**
- Natural Killer
  - Off-the-Shelf NK Cells
  - Autologous Memory ceNK

**Lead**

**Antkiva (N-803)**
- Cytokine
- Cytokine Fusion
- Antibody (IgG1)

**Aldoxorubicin**
- pH-Sensitive Hydrazine Linker
- Albumin-binding site

**Adenovirus (hAd5)**
- Nucleocapsid (N) Protein
- Spike Protein

**Mechanism of Action**

**Transaction Overview**

**Consolidated Pipeline**

**ImmunityBio**

**ImmunityBio – NantKwest Combinations**

**Closing**
## Selected Summary of Upcoming Catalysts

<table>
<thead>
<tr>
<th>Ph</th>
<th>Trial</th>
<th>Status</th>
<th>Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Bladder</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II / III</td>
<td>BCG Unresponsive NMIBC Carcinoma In-Situ (CIS) 2L</td>
<td>• Full Accrual</td>
<td>Q4 2020</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Initial Readout for FDA</td>
<td>1H 2021</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• BLA Filing</td>
<td>2H 2021</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Full Accrual</td>
<td>2H 2021</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>BCG Unresponsive NMIBC Papillary 2L</td>
<td>• Initial Readout</td>
</tr>
<tr>
<td></td>
<td><strong>Lung</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>Non-Small Cell Lung 1L CPI Chemo Free</td>
<td>• Activating Sites / Enrolling Patients</td>
<td>Ongoing</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>Non-Small Cell Lung Cancer 1L CPI + Concurrent Chemo</td>
<td>• Activating Sites / Enrolling Patients</td>
</tr>
<tr>
<td></td>
<td>IIb</td>
<td>Checkpoint Relapsed Lung 2L or Greater</td>
<td>• Confirm Registralional Protocol Design</td>
</tr>
<tr>
<td></td>
<td><strong>Pancreatic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II / III</td>
<td>Pancreatic Cancer 3L</td>
<td>• Confirm Registralional Protocol Design</td>
<td>Q2 2021</td>
</tr>
<tr>
<td></td>
<td><strong>Breast</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ib / II</td>
<td>Triple Negative Breast Cancer 2L or Greater</td>
<td>• Confirm Registralional Protocol Design</td>
<td>Q2 2021</td>
</tr>
<tr>
<td></td>
<td><strong>Glioblastoma</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>Recurrent Glioblastoma</td>
<td>• Confirm Registralional Protocol Design</td>
<td>Q1 2021</td>
</tr>
<tr>
<td></td>
<td><strong>Merkel Cell Carcinoma</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>Merkel Cell Carcinoma</td>
<td>• Activating Sites / Enrolling Patients</td>
<td>Ongoing</td>
</tr>
<tr>
<td></td>
<td><strong>COVID-19</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I / II / III</td>
<td>Human Adenovirus (hAd5) COVID-19 Vaccine (TCELLVACCINE)</td>
<td>• Phase I Readout</td>
<td>Q1 2021</td>
</tr>
</tbody>
</table>

### Transaction Overview

- **Consolidated Pipeline**
- **ImmunityBio**
- **ImmunityBio – NantKwest Combinations**
- **Closing**
Introduction to ImmunityBio

ImmunityBio – NantKwest Combinations
Overview of Non-Muscle Invasive Bladder Cancer

High rates of progression and recurrence for NMIBC make it the most expensive cancer to treat.

Current standard of treatment is Transurethral resection of bladder tumor (TURBT), with or without intravesical therapy.

Intravesical BCG is commonly used as an adjuvant treatment after TURBT for intermediate-high-risk NMIBC – side effects are common.

Up to 50% of patients fail BCG.

Patients who have failed BCG therapy require radical cystectomy with urinary diversion or chemotherapy and radiation.

Only 50% of patients undergoing radical cystectomy will survive at 5 years.

**80k**
Annual
New Cases

**18k**
Annual
Deaths

---

**Current Standard of Care**

- Intravesical BCG
- BCG Administered Intravesically

**ImmunityBio’s Approach**

- Intravesical BCG
- Anktiva
- BCG + Anktiva Administered Intravesically

BREAKTHROUGH THERAPY DESIGNATION for BCG-Unresponsive NMIBC CIS
Phase I Results in NMIBC

### Anktiva + BCG in High-Risk NMIBC – Phase I Results

<table>
<thead>
<tr>
<th>Dose (intravesicular instillation)</th>
<th>Patient</th>
<th>Stage</th>
<th>Response Assessments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>W12</td>
</tr>
<tr>
<td>100 µg</td>
<td>1</td>
<td>Pap T1</td>
<td>CR*</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>Pap Ta</td>
<td>CR*</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>Pap T1</td>
<td>CR*</td>
</tr>
<tr>
<td>200 µg</td>
<td>4</td>
<td>Pap T1</td>
<td>IC</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>CIS</td>
<td>IC</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>Pap T1</td>
<td>CR*</td>
</tr>
<tr>
<td>400 µg</td>
<td>7</td>
<td>Pap T1</td>
<td>CR*</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>CIS</td>
<td>CR*</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>Pap Ta</td>
<td>CR*</td>
</tr>
</tbody>
</table>

Data as of Feb 2018

CR – Complete Response
CR* – No Recurrence (NR) in Papillary Disease
CR** – Negative Cystoscopy Inconclusive Cytology

9 of 9 (100%) Patients Disease-Free at 24 Months

FDA granted Fast Track Designation to the pivotal trial based on this Phase I data.

Standard of Care historical response rate is 58-81% at 3-6 months post BCG alone
Phase II / III Data in BCG-Unresponsive NMIBC CIS
Ongoing Study

**Primary Endpoint**
Complete Response at Any Time

Primary Endpoint: CR at any time, with lower bound of 95% CI ≥ 20%
To meet the primary endpoint, **24** out of 80 patients must have had a CR at any time

- 80 patients accrued to date (fully accrued)
- Results: **51 CRs at any time have been reached**
- CR Rate at Any Time of **72%** (95% CI: 60%, 82%)
- SAE rate of 1%

**Secondary Endpoint**
Duration of Complete Response

- CR at 12 and 15 months
- **59%** (95% CI: 41.1%, 73.2%) probability of patients maintaining CR for 12 months

**Next Steps**

1H 2020: Initial FDA Readout Ph II / III BCG Unresponsive NMIBC Carcinoma In-Situ CIS 2nd Line

2H 2021: CIS BLA Filing Ph II / III BCG Unresponsive NMIBC

Data as of 04-Dec-2020 Cut-Off
Phase III Data in BCG-Unresponsive NMIBC Papillary

**Primary Endpoint** | Disease Free Rate at 12 Months

- Accrued 57 out of 80 patients required
  - 39 patients evaluable at 12 months
- Results to date: 19 patients out of 39 (49%) are Disease Free at 12 months (95% CI: 32%, 65%)
- Number of patients requiring cystectomy to date: 0

By end of Q2 2021: 9 current disease free patients potentially reaching 12 months

Q3 2021: Ph III BCG Unresponsive NMIBC Papillary 2nd Line Full Accrual

Q4 2021: Ph III BCG Unresponsive NMIBC Papillary Initial Readout

Data as of 04-Dec-2020 Cut-Off
Review of Unmet Need in Lung Cancer

Lung cancer is the second most common cancer in the United States

- **234k** Annual New Cases
- **154k** Annual Deaths

80-85% NSCLC

15-20% SCLC

Monoclonal antibodies targeting PD-1 and PD-L1:
Nivolumab, pembrolizumab, durvalumab and atezolizumab are FDA-approved

Current standard of care results in patient responses that may be short lived, ranging from late response to progression after achieving an initial response

Strong rationale to evaluate Anktiva + anti–PD-1 or anti–PD-L1 checkpoint inhibitor for patients with NSCLC who have relapsed after achieving an initial response to PD-1 or PD-L1 blockade therapy
Phase IIb Data in Lung Cancer
2nd and 3rd Line NSCLC

Multi-Cohort Basket and Status

- QUILT 3.055 is an ongoing Phase IIb, basket trial of 11 anatomical tumor types of combination Anktiva + checkpoint
- 131 patients have been enrolled to date
- 81 / 131 of these have lung cancer (78 NSCLC and 3 SCLC)
- Selected for Lung MAP 2L NSCLC trial

Next Steps

Dec 2020: Lung cohorts to reach full enrolment
1H 2021: Data lock anticipated for the QUILT 3.055 lung cancer cohorts

Patients Receiving Checkpoint + Anktiva

Shows preliminary evidence of long-term stable disease in 2L / 3L NSCLC patients who previously progressed

Tumor Response Over Time - NSCLC Subjects

As of December 2020
COVID-19 Vaccine
hAd5 S+N COVID-19 T Cell Vaccine

Oral vaccine offers unique advantages compared to other injection-based vaccines in development.

- **ImmunityBio’s 2nd generation platform hAd5** is “immunologically quiet” enabling immune response even in the face of antibodies
- **Reduced antigenic competition** between vector and target antigens results in **longevity of disease target protein expression**
- **Reduced adverse effects** of vector-viral proteins
- Potential **long-lasting immunity** against COVID-19
- **Mass manufacturing capacity** established for drug substance and oral capsule finished dosage form, **turnkey today**
- No needles, **self-administration; low cost distribution and storage**

Transaction Overview | Consolidated Pipeline | ImmunityBio | ImmunityBio – NantKwest Combinations | Closing
ImmunityBio’s HIV Anktiva Program

**HIV Data**
Clinical Evidence of Viremia Control in HIV Patients

- Phase I clinical dose escalation study:
  - Evidence for virus transcription
  - Suggestion of reservoir reduction in Peripheral Blood Mononuclear Cells (PBMC)
  - No evidence for production of IL-15 antibodies or cytokine side effects

**Next Steps**

Additional Ph I trial evaluating Anktiva in combination with adoptive transfer of haplo-identical NK cells

Additional protocol in development

**Patients Receiving Checkpoint + Anktiva**

Results show decrease in number of cells with measurable HIV

<table>
<thead>
<tr>
<th>Cells/Million Memory CD4s</th>
</tr>
</thead>
<tbody>
<tr>
<td>Base Line</td>
</tr>
<tr>
<td>Dose 1 Day 7</td>
</tr>
<tr>
<td>Dose 2 Day 7</td>
</tr>
<tr>
<td>Dose 3 Day 7</td>
</tr>
<tr>
<td>6 Mo</td>
</tr>
</tbody>
</table>

- 0.3 mcg
- 1.0 mcg
- 3.0 mcg
- 6.0 mcg
Overview of NantKwest NK Cell Production Platform

NantKwest platforms focused on scale production and manufacturing of NK cell types to support immunotherapy development for partners, including ImmunityBio.

**NK-92**
- **Universal NK Cell Line**
  - NKG2D
  - Nkp30, 44, 46

**Phase II**
- **Merkel Cell Carcinoma**
- **Pancreatic Cancer**
  - **June 2020**

**Phase I**
- **Lymphoma Planned 2021**
  - IND Auth. June 2019
- **Breast Cancer**
  - IND Planned Q1 2021
- **Head & Neck Cancer**
  - IND Planned 2021
- **2021 t-haNK Pipeline**

**Autologous Cytokine Enriched NK & T Cells (M-ceNK)**
- **GMP in a Box**
  - Donor Derived NK
  - GMP in a Box

**ImmunityBio – NantKwest Combinations**
- **Transaction Overview**
- **Consolidated Pipeline**
- **ImmunityBio**
- **Closing**

**ceNK**
- **Cytokine Enriched Natural Killer**

**Expansion and Cytokine Enrichment (N-003)**
- **Enriched NK & T Cell Product**
  - Aliquot & Freeze
  - Concentrate
  - CAR RNA Electroporation

**Autologous Apheresis Product**
- **Aliquot & Freeze**
- **Thaw**

ImmunityBio, Inc. – Confidential, Not for Distribution
Pancreatic Cancer Program Overview
PD.L1 t-haNK

Overview and Approach

- **279k** Annual New Cases
- **43k** Annual Deaths

Next Steps

Q1 2021: Planned end of Phase II and SPA meeting with FDA to confirm registrational protocol design for 1L, 2L and 3L indications

2L Metastatic Pancreatic Cancer Data

- Anktiva and aldoxorubicin combined with off-the-shelf NK cells and other agents showed a durable complete remission in patients with advanced disease
- 82% of patients (14 / 17) with advanced pancreatic cancer achieved disease control

Single Patient IND (spIND)
Complete Response in 2nd Line Metastatic Pancreatic Cancer

- Enrolled into Trial
- Rapid Decline of CA19-9 Levels
- July 12, 2019 Liver Metastasis Positive PET CT Response FOURRR
- November 14, 2019 Complete Response PET CT

- August 2020 Ongoing Complete Response Confirmed by PET CT
- Durably Confirmed Complete Remission
- Ongoing Complete Response By PET CT

Transaction Overview
Consolidated Pipeline
ImmunityBio
ImmunityBio – NantKwest Combinations
Closing

ImmunityBio, Inc. – Confidential, Not for Distribution
Triple Negative Breast Cancer (TNBC) Program Overview PD-L1 t-haNK

Overview and Approach

- **57k** Annual New Cases
- **47k** Annual Deaths

- Standard of care: **Checkpoint inhibitors**, such as atezolizumab

Next Steps

Q2 2021: Planned end of Phase Ib / II and SPA meeting with FDA to confirm **registrational protocol design** for 3rd line or greater TNBC registrational trials randomized against sacituzumab govitacan

TNBC Data

- Median **progression free survival** was **14.3 months** with median overall survival of **20.2 months** to date

89% (8/9) Subjects with Disease Control
Merkel Cell Carcinoma Program Overview
Anktiva + CD-16 haNK

Overview

- Standard of care: surgery, chemotherapy and radiation

- ~2.8k Annual New Cases
- 20% Patients surviving >5 years

Approach and Development Plan

- Single-arm study of Anktiva in combination with CD-16 expressing, off-the-shelf NK and avelumab (anti PD-L1 checkpoint inhibitor)
- First clinical trial patient was dosed in Phase II study in March 2020
- In the Phase I study, promising findings were noted with this combination, resulting in complete remission lasting for 4 years to date

Next Steps
Continue to add sites and seek out patients given small population of patients
Closing
Compelling Strategic Rationale for Combination

- **ImmunityBio**
  - Broad range of late-stage breakthrough designated immunotherapy platforms spanning NK and T cell platforms
  - Promising early stage clinical and pre-clinical pipeline spanning infectious disease and oncology

- **NantKwest**
  - Proprietary natural killer (NK) cell platform spanning off-the-shelf & autologous stem cell NK platform
  - Proprietary manufacturing processes and ready-to-scale facilities

- **MergeCo**
  - An immunotherapy leader focused on treating cancer and infectious diseases by orchestrating the innate (NK) and adaptive (T cell) immune system

Both companies strongly aligned in culture, operations, combination trials and collaboration agreements.
Next Steps

**Required Approvals**
- SEC clearance of registration statement / proxy
- NantKwest shareholder vote (Q1 2021)
- Transaction subject to customary closing conditions – until closing, NantKwest will continue to operate as a separate and independent company

**Timing Expectations**
- Registration statement / proxy
  - January: Submit and publicly file proxy
  - March: Shareholder vote
  - March: Close transaction
Forward-Looking Statements

• This presentation contains forward-looking statements relating to the proposed transaction involving NantKwest, Inc. ("NantKwest") and ImmunityBio, Inc. ("ImmunityBio"), including financial estimates and statements as to the expected timing, completion and effects of the proposed transaction and statements relating to NantKwest and ImmunityBio's future success in improving the treatment of various diseases and illnesses, including, but not limited to COVID-19 and cancer. Statements in this communication that are not statements of historical fact are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are usually identified by the use of words such as "anticipates," "believes," "continues", "could", "estimates," "expects," "intends," "may," "plans," "potential", "predicts", "projects," "seeks," "should," "will," and variations of such words or similar expressions. These forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of NantKwest's management and ImmunityBio's management as well as assumptions made by and information currently available to NantKwest and ImmunityBio. Such statements reflect the current views of NantKwest and ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about NantKwest and ImmunityBio, including, without limitation, (i) inability to complete the proposed transaction because, among other reasons, conditions to the closing of the proposed transaction may not be satisfied or waived, (ii) uncertainty as to the timing of completion of the proposed transaction, (iii) potential adverse effects or changes to relationships with employees, suppliers or other parties resulting from the announcement or completion of the proposed transaction, (iv) possible disruptions from the proposed transaction that could harm NantKwest's or ImmunityBio's respective business, including current plans and operations, (v) unexpected costs, charges or expenses resulting from the proposed transaction, (vi) uncertainty of the expected financial performance of the combined company following completion of the proposed transaction, including the possibility that the expected synergies and value creation from the proposed transaction will not be realized or will not be realized within the expected time period, (vii) the ability of each of NantKwest or ImmunityBio to continue its planned preclinical and clinical development of its respective development programs, and the timing and success of any such continued preclinical and clinical development and planned regulatory submissions, (viii) inability to retain and hire key personnel, and (ix) the unknown future impact of the COVID-19 pandemic delay on certain clinical trial milestones and/or NantKwest's or ImmunityBio's operations or operating expenses. More details about these and other risks that may impact our business are described under the heading "Risk Factors" in NantKwest's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission ("SEC") and in subsequent filings made by NantKwest with the SEC, which are available on the SEC's website at www.sec.gov. NantKwest and ImmunityBio caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. NantKwest and ImmunityBio do not undertake any duty to update any forward-looking statement or other information in this communication, except to the extent required by law. No representation is made as to the safety or effectiveness of these product candidates for the therapeutic use for which such product candidates are being studied.

• Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and NantKwest's and ImmunityBio's own internal estimates and research. While NantKwest and ImmunityBio believe these third-party sources to be reliable as of the date of this communication, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this communication involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while NantKwest and ImmunityBio each believes its own internal research is reliable, such research has not verified by any independent source.
Additional Information and Where to Find It

• This presentation is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy, sell or solicit any securities or any proxy, vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be deemed to be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933.

• In connection with the proposed transaction, NantKwest intends to file a registration statement on Form S-4 with the SEC, which will include a prospectus and joint solicitation statement of NantKwest and ImmunityBio (the “solicitation statement/prospectus”). NantKwest may also file other documents regarding the proposed transaction with the SEC. This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. This communication is not intended to be, and is not, a substitute for such filings or for any other document that NantKwest may file with the SEC in connection with the proposed transaction. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO CAREFULLY READ THE ENTIRE REGISTRATION STATEMENT AND SOLICITATION STATEMENT / PROSPECTUS, WHEN THEY BECOME AVAILABLE, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain free copies of the registration statement and solicitation statement/prospectus and other documents filed with the SEC by NantKwest through the website maintained by the SEC at www.sec.gov. In addition, investors and security holders will be able to obtain free copies of the prospectus and other documents filed with the SEC on NantKwest’s website at www.ir.nantkwest.com.

• NantKwest and certain of its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from stockholders of NantKwest in connection with the proposed transaction under the rules of the SEC. Investors may obtain information regarding the names, affiliations and interests of directors and executive officers of NantKwest in NantKwest’s proxy statement for its 2020 annual meeting of stockholders, which was filed with the SEC on April 24, 2020, as well as its other filings with the SEC. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be included in the registration statement, solicitation statement / prospectus and other relevant materials to be filed with the SEC by NantKwest regarding the proposed transaction (if and when they become available). You may obtain free copies of these documents at the SEC’s website at www.sec.gov. Copies of documents filed with the SEC will also be available free of charge from NantKwest using the sources indicated above.